<DOC>
	<DOCNO>NCT02371096</DOCNO>
	<brief_summary>Pharmacokinetic property , efficacy , safety tolerability RGB-03 MabThera compare patient suffer Rheumatoid Arthritis .</brief_summary>
	<brief_title>Comparative Pharmacokinetic Trial RGB-03 MabThera</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Active Rheumatoid Arthritis Inadequate response intolerance DMARDs antiTNFs Treatment Methotrexate Previous treatment rituximab Patients systemic manifestation rheumatoid arthritis Patients seropositive HIV , HCV , HBV Female patient nurse Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>